
Enzybel Pharma 2 and Deebio partner to address pancrelipase shortages
Ella Day | August 15, 2025 | News story | Manufacturing and Production, Mergers and Acquisitions | Deebio, Enzybel Pharma 2, Gastrointestinal tract, Natix, pancrelipase
Enzybel Pharma 2, part of European distributor Natix, has formed an alliance with Chinese enzyme manufacturer Deebio to help alleviate the global shortage of high-activity pancrelipase (pancreatin). The partnership will focus on producing a highly purified, standardised form of the active pharmaceutical ingredient (API), used in the treatment of pancreatic insufficiency.
To meet European and US regulatory requirements, Deebio is developing a dedicated manufacturing facility for pancrelipase production. The plant will use an automated process designed to meet current Good Manufacturing Practice standards in both regions.
Under the agreement, Enzybel Pharma 2 has secured exclusive sales rights for the product in Europe and the US. The companies aim to increase supply in response to ongoing shortages, with pancrelipase playing a critical role for patients who rely on enzyme replacement therapy.
“This partnership represents a major milestone for both Enzybel Pharma 2 and Deebio,” said both Stefaan Vandaele, CEO of Natix, and Bilqees Khan, co-founder of Enzybel Pharma 2.
The collaboration will also focus on optimising manufacturing and distribution processes to ensure a stable and compliant supply chain. The companies hope that the initiative will improve patient access to essential medication in multiple countries.
Ella Day
15/8/25
Related Content

AbbVie financials beat expectations
AbbVie has announced higher-than-expected financial results for the third quarter of 2014, although it continues …






